CELLS OF A GENERATION C.I.C.

Company limited by guarantee

Company Registration Number:
14740748 (England and Wales)

Unaudited statutory accounts for the year ended 31 March 2025

Period of accounts

Start date: 1 April 2024

End date: 31 March 2025

CELLS OF A GENERATION C.I.C.

Contents of the Financial Statements

for the Period Ended 31 March 2025

Profit and loss
Balance sheet
Additional notes
Balance sheet notes
Community Interest Report

CELLS OF A GENERATION C.I.C.

Profit And Loss Account

for the Period Ended 31 March 2025

2025 2024


£

£
Turnover: 15,140 9,969
Cost of sales: ( 1,541 )
Gross profit(or loss): 13,599 9,969
Administrative expenses: ( 10,089 ) ( 11,970 )
Other operating income: 163
Operating profit(or loss): 3,510 (1,838)
Profit(or loss) before tax: 3,510 (1,838)
Tax: ( 318 )
Profit(or loss) for the financial year: 3,192 (1,838)

CELLS OF A GENERATION C.I.C.

Balance sheet

As at 31 March 2025

Notes 2025 2024


£

£
Current assets
Cash at bank and in hand: 3,559 393
Total current assets: 3,559 393
Creditors: amounts falling due within one year: 3 ( 2,205 ) ( 2,231 )
Net current assets (liabilities): 1,354 (1,838)
Total assets less current liabilities: 1,354 ( 1,838)
Total net assets (liabilities): 1,354 (1,838)
Members' funds
Profit and loss account: 1,354 ( 1,838)
Total members' funds: 1,354 (1,838)

The notes form part of these financial statements

CELLS OF A GENERATION C.I.C.

Balance sheet statements

For the year ending 31 March 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 29 December 2025
and signed on behalf of the board by:

Name: Sharon Browne-Peter
Status: Director

The notes form part of these financial statements

CELLS OF A GENERATION C.I.C.

Notes to the Financial Statements

for the Period Ended 31 March 2025

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Turnover policy

    Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards ofownership ofthe goods have transferred to the buyer. Turnover from the renderingof services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

CELLS OF A GENERATION C.I.C.

Notes to the Financial Statements

for the Period Ended 31 March 2025

  • 2. Employees

    2025 2024
    Average number of employees during the period 0 1

CELLS OF A GENERATION C.I.C.

Notes to the Financial Statements

for the Period Ended 31 March 2025

3. Creditors: amounts falling due within one year note

2025 2024
£ £
Other creditors 2,205 2,231
Total 2,205 2,231

COMMUNITY INTEREST ANNUAL REPORT

CELLS OF A GENERATION C.I.C.

Company Number: 14740748 (England and Wales)

Year Ending: 31 March 2025

Company activities and impact

Cells of a Generation C.I.C. works to address health inequalities related to sickle cell disorder, with a particular focus on increasing awareness and encouraging blood donation among Black and ethnically diverse communities. During the year ended 31 March 2025, the company delivered a programme of community engagement, education, and creative health advocacy designed to make information about sickle cell disorder accessible, culturally relevant, and engaging. Key activities during the year included: The development and delivery of The Crisis Saga, a comic book series used as an educational tool to engage young people and community audiences in conversations about sickle cell disorder and blood donation. The production of The Lifeline Conversations, a short documentary exploring lived experiences of sickle cell disorder and the motivations behind blood donation, using personal storytelling to encourage behavioural change. Delivery of workshops and outreach sessions, including virtual workshops and in-person sessions at Enfield College and Tottenham College, using visual storytelling to support health education. Community and cultural outreach at venues including Kindred (Hammersmith) and Recess Land (Margate), engaging audiences in informal and accessible settings. Through these activities, the company contributed to increased awareness of sickle cell disorder and the importance of blood donation, particularly among first-time donors. Feedback from workshops, screenings, and outreach events indicated that creative and interactive formats were effective in encouraging dialogue, addressing misconceptions, and reducing barriers to donation. The company’s work supported NHS Blood and Transplant’s wider efforts to increase donor engagement and helped foster greater understanding of the need for ethnically matched blood donations for people living with sickle cell disorder. Looking ahead, the company intends to build on this work by developing The Lifeline Conversations into a recurring engagement format, expanding digital engagement through its website and media platforms, continuing partnership work with NHS Blood and Transplant, and strengthening relationships with educational institutions and creative collaborators to sustain long-term community impact.

Consultation with stakeholders

The company’s stakeholders during the year included: 1. Individuals living with sickle cell disorder and their families 2. NHS Blood and Transplant (NHSBT) 3. Artists, educators, and community partners 4. The directors of the company The directors were actively involved in shaping and reviewing the company’s activities and community engagement approach throughout the year. Regular discussions between directors informed strategic decisions, programme design, and priorities for outreach and partnerships, ensuring that the company’s activities aligned with its community interest purpose. The company maintained ongoing engagement with NHS Blood and Transplant through quarterly discussions. These consultations informed the timing, focus, and messaging of outreach activities, particularly in response to periods of reduced blood supply. Engagement with individuals with lived experience of sickle cell disorder, alongside feedback gathered during workshops, screenings, and outreach events, helped ensure that activities remained accurate, respectful, and community-led. Feedback was used to refine creative formats, improve accessibility, and strengthen messaging around blood donation.

Directors' remuneration

The total amount paid or receivable by directors in respect of qualifying services was £1210 There were no other transactions or arrangements in connection with the remuneration of directors, or compensation for director’s loss of office, which require to be disclosed

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
29 December 2025

And signed on behalf of the board by:
Name: Sharon Browne-Peter
Status: Director